J&J, BioMotiv invest $13M in Philly’s Aro Biotherapeutics and its Centyrin protein cancer drugs
The company, based at the University of Pennsylvania’s Pennovation Center, is trying to develop therapies for "undruggable disease."
Pennovation, home to research labs, business and entrepreneurial offices, and educational facilities, will be officially dedicated in two weeks. (Margo Reed / File photo)Read more
